Irma Bagdoniene: Extreme Lipoprotein(a) Equals Secondary Prevention Risk in FH Patients
Irma Bagdoniene, Cardiologist and Lipidologist at Klinikum Lippe – University Hospital for Cardiology, Angiology, and Internal Intensive Care Medicine, posted on LinkedIn:
“This study highlights a important message: patients with extreme elevations of Lp(a) already carry a cardiovascular risk equivalent to secondary prevention — even in the primary prevention setting.
Implications for clinical practice:
- LDL-C targets of ≤70 mg/dL, ideally ≤55 mg/dL, are fully justified.
- Achieving these levels often requires combination therapy, including PCSK9 inhibitors.
- These high-risk patients deserve early, intensive lipid management—not only after their first event.
A strong reminder: FH AND extreme Lp(a) is a double-hit dyslipidemia that demands aggressive and early prevention strategies.”
Title: Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia
Authors: Martine Paquette, MSca, Bertrand Cariou, MDb, Simon-Pierre Guay, MDa,c,d, Antonio Gallo, MDe, Liam R. Brunham, MDf, Sophie Béliard, MDg, Alexis Baass, MD
Read full article here.
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals